ASCO GU 2026

Combination is the way to go - but how to select?

Encouraging new data in Prostate cancer

Precision medicine for prostate cancer

Actinium radioligand therapy

Radium-223 + Enzalutamid

EZH2 oral molecule to enhance ARPI

Prolonged PSA declines with normalization of…

T-cell engager - first in human

Neoadjuvant therapy after molecular biopsy testing

T-Cell-Engager

New Mode of Action in mCRPC

Benefit of PARPi + ABI combination

Post-IO in RCC: Promising Efficacy, Evolving Survival…

Early SBRT shows safety, no added benefit

Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab

Treatment after immunotherapy in aRCC: always a complex…

Belzutifan + Lenvatinib: A New Second-Line Approach in…

Upcoming new standard for adjuvant RCC

Advances in the Adjuvant Treatment of RCC

Combination therapy in adjuvant RCC

Real World Data - RCC

New follow-up therapy with lenvatinib + belzutifan

Long‑term effects of adjuvant therapy

HIF based combination are here to stay

Balancing efficacy and toxicity: the challenge in high…

Equilibrar eficacia y toxicidad: el desafío en el ccRCC…

The future is bright, but complex

Important steps towards biomarker driven treatment of…

Closing the gap for platin eligibility

EV+P new SOC in MIBC

Urinary ctDNA vs. plasma ctDNA

Rethinking the use of HER2neu in routine clinical…

Promising data - how to stratify the patients for the…

ctDNA testing: Who, how and how often?

New perioperative standard for MIBC

MIBC - time for a historic paradigm shift?

ctDNA dynamics in the IMvigor011 trial

Perioperative EV + P - the new standard?!

pCR in MIBC under EV + P

A new class of drug in luminal UC

New machanism of action in pts with UC

Perioperative EV+Pembrolizumab in MIBC

Une nouvelle classe de médicaments pour le carcinome…

Dinámica del ctDNA en el ensayo IMvigor011

EV + P : nouveau standard de traitement pour le TVIM